DOCKET NO.: CELL-0307/PA534-USW01 **PATENT**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

David Paul Humphreys, et al.

Confirmation No.: 6569

Application No.: 10/562,807

Group Art Unit: Not Yet Assigned

Filing Date: July 6, 2006

Examiner: Not Yet Assigned

For: MODIFIED ANTIBODY FRAGMENTS

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

冈 In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified application as set forth in § 1.491, before the mailing date
	of a first Office Action on the merits of the above-identified application, or
	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).
\boxtimes	Copies of reference numbers $1 - 26$ and $34 - 46$ listed on the attached Form
	PTO-1449 are enclosed herewith.
\boxtimes	Copies of reference numbers 27 - 33 on the attached Form PTO 1449 are not
	required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application

The relevance of those listed references	which	are not	in th	e English	language	is	as
follows:							

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-

3050. This form is submitted in duplicate.

Date: October 6, 2006

Jane E. Inglese

Registration No. 48,444

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2006 WW



Form P	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. CELL-0307/PA534-USw01	Application No. 10/562,807	
List of Pa			Applicant David Paul Humphreys, et al.		
		ent of Commerce rademark Office	Filing Date July 6, 2006	Group Not Yet Assigned	
			Confirmation No. 6569		
NON-P	ATI	ENT DOCUMENTS (Inc	cluding Author, Title, Date,	Pertinent Pages, Etc.)	
. 1	1			ion of disulfide adducts ith highly reactive cysteines," J.	
. 2	2			ins," Science, 1988, 242, 423	
3	3	Burns, J., et al., "Selective J. Org. Chem., 1991, 56,		tris(2-carboxyethyl)phosphine,"	
4	4	Chapman, A.P., et al., "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotechnology</i> , 1999 , <i>17</i> , 780-783			
	5	Chapman, A.P., et al., "PEGylated antibodies and antibody fragments for improved therapy: a review," <i>Advanced Drug Delivery Reviews</i> , 2002 , <i>54</i> , 531-545			
	6		"Receptor-mediated and enges," Pharmacology and There	zyme-dependent targeting of apeutics, 1999, 83, 67-123	
	7		oreduction of monoclonal ant niques, 2000, 28(2), 324-326	ibodies for conjugation and	
. 8	8	Getz, E.B., et al., "A concarboxyethyl)phosphine Analytical Biochemistry,	nparison between the sulfhyd and dithiothreitol for use in p 1999, 273, 73-80	ryl reductants tris(2- protein biochemistry,"	
	9	Han, J.C., et al., "A procedure for quantitative determination of Tris(2-carboxyethyl)phosphine, an orderless reducing agent more stable and effective than dithiothreitol," <i>Analytical Biochemistry</i> , 1994 , 220, 5-10			
	10	Hellstrom, K.E., et al., "LEd., Robinson, et al. (Ed.		" Controlled Drug Delivery, 2 nd	
	11	hinge size and isotype, p	"Formation of dimeric fabs i resence of interchain disulphes and growth conditions," J		

EXAMINER	DATE CONSIDERED

		T			
Form PT	O-1449 Modified	Docket No. CELL-0307/PA534-USw01	Application No. 10/562,807		
Cited	ent and Publications I by Applicant I sheets if necessary)	Applicant David Paul Humphreys, et	al.		
	tment of Commerce I Trademark Office	Filing Date July 6, 2006	Group Not Yet Assigned		
		Confirmation No. 6569			
NON-PA	TENT DOCUMENTS (Inc	cluding Author, Title, Date	, Pertinent Pages, Etc.)		
. 12	Escherichia coli: importa		nization of Fab' production in in and light chain synthesis," 20		
13	Humpineys, D.I., et al.,	"Efficient site specific remore copper (II) ion catalysed pro			
. 14	Leach, S.J., et al., "The 6	Leach, S.J., et al., "The electrolytic reduction of proteins," Div. Protein Chem., 1965, 4, 23-27			
15	interleukin-8 antibody fo	Leong, S.R., et al., "Adapting pharmacokinetic properties of a humanized anti- interleukin-8 antibody for therapeutic applications using site-specific pegylation," <i>Cytokine</i> , 2001 , <i>16</i> , 106-119			
16		Lyons, A., et al., "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues," <i>Protein Engineering</i> , 1990 , <i>3</i> , 703-708			
17	Mountain, A., et al., "En Rev., 1992, 10, 1-142	gineering antibodies for ther	apy," Biotechnol. Genet. Eng.		
18	polymerase chain reaction	on," Proc. Natl. Acad. Sci. U.			
19	Riechmann, L., et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988 , <i>32</i> 323				
20	Rodrigues, M.L., et al., "Engineering Fab' fragments for efficient F(ab) ₂ formation in Escherichia coli and for improved in vivo stability," The Journal of Immunology, 1993, 151, 6954-6961				
21	Rüegg, U.T., et al., "Reduction cleavage of cyustine disulfides with tributylphosphine," <i>Methods in Enzymology</i> , 1977 , <i>47</i> , 111-126				
22	Seitz, U., et al., "Prepara antigen monoclonal antib 1265-1273	tion and evaluation of the rh body BW 250/183," Euro. J.	enium-188-labelled anti-NCA Nuclear Medicine, 1999, 26,		
23	Enzymology, 1995, 251,		,		
24	Thorpe, P.E., et al., "The conjugates," <i>Immunol. R</i>	e preparation and cytotoxic p ev., 1982, 62, 119-158	roperties of antibody-toxin		
		·			

EXAMINER	DATE CONSIDERED

		-1449 Modified	Docket No. CELL-0307/PA534-USw01	Application No. 10/562,807	
			Applicant David Paul Humphreys, et al.		
		nent of Commerce Frademark Office	Filing Date July 6, 2006	Group Not Yet Assigned	
			Confirmation No. 6569		
NON-	PATI	ENT DOCUMENTS (Inc	cluding Author, Title, Date,	Pertinent Pages, Etc.)	
-	25			of bacterial, yeast, insect and Methods, 1998, 216, 165-181	
-	26	Ward, E., et al., "Binding	g activities of a repertoire of s scherichia coli," Nature, 198	single immunoglobulin variable	
•					
•					

	EXAMINER	DATE CONSIDERED
1		

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Docket No. CELL-0307/PA534-USw01 Application No. 10/562,807

Applicant

David Paul Humphreys, et al.

Filing Date July 6, 2006

Group
Not Yet Assigned

Confirmation No. 6569

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
•	27	4,741,900	05/03/88	Alvarez, et al.	424	85
	28	4,816,397	03/28/89	Boss, et al.	435	68
	29	5,219,996	06/15/93	Bodmer, et al.	530	387.3
	30	5,585,089	12/17/96	Queen, et al.	424	133.1
•	31	5,665,866	09/09/97	Weir, et al.	530	390.5
	32	5,677,425	10/14/97	Bodmer, et al.	530	387.1
-	33	6,331,415 B1	12/18/01	Cabilly, et al.	435	69.6
				-		
			1		.=	
_						
<u>,</u>						
			-			

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified				Docket No. CELL-0307/PA534-USw01	Application No 10/562,807	0.
List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office			Applicant David Paul Humphreys, et al.			
			Filing Date July 6, 2006	Group Not Yet Assigned		
				Confirmation No. 6569		
		FORE	IGN PATE	ENT DOCUMENTS		
Examiner Initial		Document No.	Date	Country	Transl YES	ation NO
•	34	WO 89/01476 A1	02/23/89	PCT		
	35	WO 90/09195 A1	08/23/90	PCT	-	
	36	WO 91/09967 A1	07/11/91	PCT		
	37	WO 92/02551 A1	02/20/92	PCT		
•	38	WO 92/22583 A2	12/23/92	PCT		
•	39	WO 93/06231 A1	04/01/93	PCT		
,-	40	WO 97/36932 A1	10/9/97	PCT		
	41	WO 98/25971 A1	06/18/98	PCT	N.**1	
	42	WO 98/37200	08/27/98	PCT		

EXAMINER	DATE CONSIDERED

04/01/99 PCT

04/17/03 PCT

EP

EP

05/19/04

11/02/94

43

44

45

46

WO 99/15549 A3

WO 03/031581 A3

1 419 786 A1

3 927 45 B1